FDA approves revumenib for relapsed or refractory acute leukemia On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.

Important approval in a difficult to treat cohort leukemia #revumenib, a menin inhibitor, for #relapsedAML with #KMT2Atranslocation in adult and pediatric patients 1 year and older.

www.fda.gov/drugs/resour...